ABSTRACT
Objective: To identify serum autoantibody biomarkers by an tumor-associated antigens (TAAs)-based microarray in the patients with esophageal precancerous lesions (EPLs) and patients with esophageal cancer (EC). Methods: The antigens microarray with 55 TAAs was used to detect the serum autoantibodies of the residency-, age-, and sex-matched 26 pairs, which included 26 cases with EC, 26 cases with EPLs and 26 normal controls. The cut-off value was defined as mean ± 2 standard deviation of the expression levels of the antibodies in the normal control group. The value corresponding to the expression level of the antibody beyond the range of cut-off value was considered seropositive. Results: Five autoantibodies (CYFRA21-1, CA72-4, NY-ESO-1, GAGE-7 and SCCA) were significantly up-regulated, and others were down-regulated. Twenty-five autoantibodies had significant difference among EC, EPLs and normal controls which were found by multi-factor analysis of variance. Serum antibodies could be detected by 9 antigens, including CA72-4, CCNB1, CDKN2A, NY-ESO-1, CYFRA21-1, E2F1, ERBB2, GAGE-7 and SCCA. The positive detection rates of CYFRA21-1 were the highest in EC and EPLs, which were 61.54% and 60.00%, respectively. Furthermore, other antigens with higher seropositive rates were NY-ESO-1 (50.00% for EC, 52.00% for EPLs), SCCA (46.15% for EC, 48.00% for EPLs), GAGE-7 (46.15% for EC, 24.00% for EPLs) and CA72-4 (34.62% for EC, 16.00% for EPLs) in turn. The seropositive rates of these 9 antigens in combined detection panel were 88.46% and 84.00% for EC and EPLs, respectively. Conclusion: CYFRA21-1 is possibly used as an autoantibody indicator for early screening of EC and EPLs. The combined detection of the 9 antigens is likely to improve the sensitivity of autoantibody detection in EC and EPLs serum samples. Copyright © 2013 by TUMOR.
ABSTRACT
This study examined associations between MTHFR C677T polymorphism and serum folate concentrations with the risk of esophageal precancerous lesions (EPL) and esophageal squamous cell carcinoma (ESCC). The highest quartile of serum folate concentration significantly decreased the risk of ESCC compared with the lowest quartile (OR=0.11; 95% Cl, 0.04-0.33; P<0.05). MTHFR 677 C>T polymorphism was associated with the risk of ESCC by using chi-square tests (P<0.05). For the CT genotype, the risk of ESCC significantly increased in study participants with low serm folate concentrations (≤26.92 μg/L) compared with participants with high serum folate concentrations (>26.92 μg/L) by using multinomial logistic regression models. The MTHFR genotype may further modify associations between serum folate concentrations and the risk of ESCC, but it was not significantly associated with the risk of EPL.